Core Viewpoint - Haima Cloud is positioned as a leading provider of GPUaaS in China, focusing on real-time cloud rendering services for various industries, including gaming and digital entertainment, with a strategic plan for IPO in 2025 [2][3]. Group 1: Company Overview - Established in 2013, Haima Cloud is the first company in China to design and develop its own servers for real-time cloud rendering [2]. - Since 2019, the company has strategically deployed GPUaaS on a large scale, becoming the largest provider of real-time cloud rendering services in China [2]. - As of December 31, 2024, Haima Cloud serves nine out of the top ten market participants in China's cloud gaming industry and has partnerships with major players like China Mobile and leading game developers [2]. Group 2: Market Position - According to Zhaosheng Consulting, Haima Cloud ranks first among real-time cloud rendering service providers in China's cloud gaming sector, holding a market share of 17.9% based on 2024 revenue [3]. Group 3: Infrastructure and Expansion - Haima Cloud operates over 10,000 GPU servers and 63 high-performance GPU computing nodes globally, making it one of the largest and most widely distributed GPU computing infrastructures for real-time cloud rendering in China [4]. - The company has established computing nodes in countries such as Singapore and Vietnam, with ongoing deployments in the UK, France, Germany, Japan, South Korea, Australia, Poland, and Canada [4]. Group 4: Financial Performance - Revenue figures for Haima Cloud from 2022 to 2024 are as follows: CNY 290 million, CNY 337 million, and CNY 520 million, reflecting a compound annual growth rate (CAGR) of 33.8% [4]. - Gross profit for the same period was CNY 62 million, CNY 89 million, and CNY 129 million, with a CAGR of 44.9% [4]. - The gross margin percentages were 21.2%, 26.6%, and 24.9% for the years 2022, 2023, and 2024, respectively [4]. Group 5: IPO Fund Utilization - The net proceeds from the IPO will primarily be used for continuous infrastructure investment, funding R&D related to core platform software, developing and promoting emerging products, and supporting ongoing development of gaming AI capabilities [5].

Core Viewpoint - Siwei Zhihui (Nanjing) Technology Co., Ltd. is preparing for an IPO on the Hong Kong Stock Exchange, with CITIC Securities as the sole sponsor, aiming to enhance its market position in the intelligent cockpit solutions sector [2][3]. Company Overview - Founded in 2015, Siwei Zhihui is a supplier of intelligent cockpit solutions, controlled by Siwei Tuxin Group. As of 2024, it ranks tenth among domestic primary intelligent cockpit solution providers with a market share of 0.1%, and third among software-driven primary suppliers globally [3]. - The company has delivered over 15.9 million intelligent cockpit software solutions and more than 1.55 million integrated hardware-software solutions to approximately 20% of China's vehicle manufacturers [3]. Financial Performance - Revenue figures for Siwei Zhihui from 2022 to 2024 are as follows: 539 million RMB, 477 million RMB, and 479 million RMB. The gross margins during the same period were 30.2%, 29.4%, and 29.2%, respectively. Adjusted net losses were 14 million RMB, 60 million RMB, and 133 million RMB [3]. Investment and Valuation - Major investors in Siwei Zhihui include Didi, MediaTek, Yihua Fund, Tencent, and others. Didi holds a 16.46% stake, making it the largest external investor [4]. - Following the last round of financing before the IPO in August 2024, Siwei Zhihui's valuation reached 4.07 billion RMB. The funds raised from the IPO will primarily be used for capacity building, technology research and development, and general corporate purposes [5].

Core Viewpoint - Jingze Biopharmaceuticals is preparing for an IPO on the Hong Kong Stock Exchange, focusing on reproductive and ophthalmic drugs, and is one of the leading companies in China with the most clinical-stage macromolecule drugs in these fields [1][3]. Summary by Sections - Jingze Biopharmaceuticals submitted its prospectus for an IPO on June 27, 2025, with CICC and Guoyuan International as joint sponsors. The company, established in 2014, specializes in reproductive and ophthalmic drugs [1]. - As of June 20, 2025, Jingze's core product in reproductive treatment, JZB30 (rhFSH lyophilized powder injection), has been approved for commercialization, while JZB33 (rhFSH aqueous injection) has submitted an NDA. In the ophthalmic field, JZB05 (anti-VEGF intravitreal injection) is undergoing Phase III clinical trials at over 40 centers in mainland China [2][3]. - JZB30 is Jingze's first commercialized product in reproductive treatment, serving as a follicle-stimulating hormone for ovulation induction. JZB05 is expected to be the first commercial product in the ophthalmic field, targeting diseases like wAMD and DME. JZB30 is a biosimilar to the leading imported product, while JZB05 is a biosimilar to the top-selling anti-VEGF drug, with the latter projected to achieve $9.5 billion in annual sales by 2024 [4]. - Since its inception, Jingze Biopharmaceuticals has completed financing totaling 927 million yuan, with a valuation of 3.09 billion yuan following its last round of financing before the IPO. The net proceeds from the IPO will primarily be used to advance core product development, clinical trials for key products, and general corporate purposes [4].

Core Viewpoint - Rongrui Technology focuses on green manufacturing in fields such as industrial enzyme preparations, health foods, pharmaceutical chemicals, and functional new materials, leveraging synthetic biology and artificial intelligence to develop disruptive technologies for green bio-manufacturing [1][2]. Group 1: Company Overview - Rongrui Technology was established in 2022 and has successfully developed dozens of products, including key industrial enzyme varieties such as lipase and amide enzymes, as well as high-value fine chemicals and health products [1]. - The company has formed multiple collaborations with leading enterprises in its niche sectors [1]. Group 2: Recent Financing - Rongrui Technology recently completed nearly 100 million yuan in Pre-A round financing, led by PwC Capital and Dinghui VGC, with Kai Cheng Capital serving as the exclusive financial advisor [1]. - The funds raised will primarily be used to accelerate product pipeline development and continue the industrialization and commercialization processes [1]. Group 3: Management and Investor Insights - The CEO of Rongrui Technology expressed gratitude for the support from investors and emphasized the company's commitment to enhancing technology, production facilities, and commercial channels to ensure sustained growth [2]. - Investors from PwC Capital and Dinghui VGC highlighted the team's extensive industrial experience and solid R&D foundation, expressing confidence in the company's growth prospects and its ability to create social value through its strong technology platform [3].

Core Viewpoint - The article emphasizes that Huaxing Capital is strategically transitioning into the WEB 3.0 and digital asset sectors, aiming to become a core player in global WEB 3.0 investments while leveraging its existing strengths in traditional finance [1][5]. Personnel Changes - Huaxing Capital appointed Frank Fu Kan and Chen Jiali as independent non-executive directors, both bringing extensive industry experience, particularly in blockchain technology and digital currencies [2]. Business Strategy - The company has approved a budget of $100 million to develop its WEB 3.0 business and invest in digital currency assets over the next two years, focusing on stablecoins, RWA (real-world assets), and the entire digital asset ecosystem [1][5]. - The board's strategic move is part of Huaxing's "2.0 era" initiative, which aims to solidify its existing business while expanding into new technology-driven sectors [3][5]. Performance and Achievements - Huaxing Capital has shown a strong recovery in its overall business, particularly in artificial intelligence and mergers and acquisitions, with significant IPO successes, including the notable performance of Circle Internet Group [3][4]. - The company has a history of successful investments in the blockchain sector, including leading roles in the IPOs of various tech firms [4]. Future Outlook - The strategic focus on artificial intelligence, mergers and acquisitions, and blockchain technology positions Huaxing Capital as a bridge between Web 2.0 and Web 3.0, enhancing its industry leadership and shareholder value [5].

Core Viewpoint - The article discusses the upcoming IPO of Weimai, a leading AI-driven full-cycle management service provider in China, highlighting its growth potential and market position in the healthcare sector [2][3][5]. Group 1: Company Overview - Weimai, established in 2013, focuses on utilizing AI technology to enhance healthcare services by connecting hospitals, doctors, and patients, thereby restructuring the value chain of medical services [3]. - As of June 20, 2025, Weimai has signed contracts with 157 hospitals and has provided full-cycle management services to approximately 500,000 patients across over 80 disease categories [12][13]. Group 2: Financial Performance - Weimai's revenue is projected to grow from RMB 511.9 million in 2022 to RMB 652.7 million in 2024, representing a 27.5% increase, driven by stable growth in full-cycle management service income [7]. - The gross margin is expected to improve from 17.2% in 2022 to 19.9% in 2024, indicating enhanced operational efficiency [7]. - Adjusted net losses are forecasted to decrease significantly from RMB 233.3 million in 2022 to RMB 30.2 million in 2024, with the adjusted net loss margin narrowing from 45.6% to 4.6% [8]. Group 3: Market Potential - The full-cycle management market in China has grown from RMB 16.3 billion in 2020 to an estimated RMB 61.4 billion in 2024, with a projected compound annual growth rate (CAGR) of 34.6% reaching RMB 365.4 billion by 2030 [15]. - The shift in China's healthcare model towards comprehensive management solutions is driven by government initiatives, creating strategic opportunities for companies like Weimai to enhance hospital efficiency and patient care [14][16]. Group 4: Investment and Future Plans - Weimai has attracted investments from notable firms and government funds, with IPO proceeds aimed at enhancing AI capabilities, expanding service offerings, and strategic acquisitions in specialized medical sectors [17].

Core Viewpoint - Yunyinggu Technology Co., Ltd. is set to go public on the Hong Kong Stock Exchange, marking a significant step after previous attempts to list in A-shares and a failed acquisition by Huida Technology [2][5]. Company Overview - Established in 2012, Yunyinggu specializes in AMOLED display driver chip design, providing solutions for consumer electronics brands [2]. - As of 2024, Yunyinggu is the largest AMOLED display driver chip manufacturer in mainland China and the fifth largest globally, according to Frost & Sullivan [2][3]. Technology and Market Position - The company has developed a comprehensive self-research display driver technology, covering chip design, compensation algorithm development, and pixel compensation circuit layout [3]. - By the end of 2024, Yunyinggu's AMOLED display driver chips will have been shipped to multiple leading smartphone brands, accounting for over 25% of the global market share [3]. Sales Performance - From 2022 to 2024, Yunyinggu's sales volume of AMOLED display driver chips increased from approximately 14.1 million to 51.4 million units, with a compound annual growth rate (CAGR) of 71.3% [4]. - The company's market share in the global smartphone AMOLED display driver chip supply rose from 1.2% in 2022 to 4.0% in 2024 [3]. Financial Performance - Yunyinggu's revenue for the years 2022, 2023, and 2024 was approximately 551 million, 720 million, and 891 million yuan, respectively [5]. - The gross profit margins for the same period were 31.9%, 0.4%, and 2.5%, with adjusted net profit margins of 0.1%, -30.2%, and 25.1% [5]. IPO Fund Utilization - The funds raised from the IPO will primarily support the research and optimization of AMOLED TDDI chips, development of Micro-OLED and Micro-LED display driver backplanes, strategic investments or acquisitions, and general working capital [5].

MVR-T3011为潜在同类最佳膀胱癌溶瘤免疫疗法，有望改变全球膀胱癌治疗格局。 本文为IPO早知道原创 作者｜罗宾 来源：公司招股书 微信公众号｜ipozaozhidao 据 IPO早知道消息，6月25日，亦诺微医药Immvira Bioscience向港交所递交招股书，花旗、中金 为联席保荐人。 亦诺微医药是 全球唯一一家具备成熟的 CMC及生产能力的生物技术公司， 致力于通过自主知识产 权的生物工程化技术，发现、开发、生产及商业化新型溶瘤免疫疗法和工程化外泌体疗法 。 公司管线组合包括用于治疗实体瘤的溶瘤免疫疗法候选药物和具临床应用前景或可直接商业化的创新 型工程化外泌体治疗产品。 亦诺微核心产品 MVR-T3011是一种基于HSV-1的新型溶瘤免疫疗法，其独特之处在于将强效的肿 瘤裂解与表达抗 PD-(L)1 抗体和 IL-12 相结合，靶向治疗全谱系膀胱癌及包含头颈鳞癌的更广泛 实体瘤类型。 凭借自主优化的 HSV-1骨架，MVR-T3011的复制能力提升了3个10级对数，支持多 途径给药，包括肿瘤内给药、膀胱内给药及静脉给药，极大地拓展了其临床适用性。 在临床研究中， MVR-T3011展现出了卓 ...

Core Viewpoint - SAINT BELLA Inc. has successfully listed on the Hong Kong Stock Exchange, becoming the "first stock of global family quality care" with significant investor interest and a strong market debut [2][4]. Company Overview - Founded in 2017, SAINT BELLA has rapidly grown to become the largest postpartum care group in China and Asia, operating in 30 cities globally [4][5]. - The company operates 96 high-end postpartum care centers under various brands, with a mix of self-operated and managed centers [5][6]. Business Expansion - SAINT BELLA has expanded its services beyond postpartum care to include family care services and functional health foods for women, enhancing customer lifecycle value [5][6]. - The company has established a significant presence in international markets, including Hong Kong, Singapore, and the United States [5][6]. Financial Performance - Revenue growth from 2022 to 2024 shows an increase from 472 million to 799 million yuan, with a return to profitability in 2023 [7]. - The adjusted net profit for 2023 was 20.77 million yuan, increasing to 42.25 million yuan in 2024 [7]. Market Position - SAINT BELLA holds a market share of approximately 1.2% in the Chinese postpartum care sector, making it the largest and fastest-growing group in this industry [6][7]. - The company has a strong customer retention rate, with 84% of postpartum care clients also utilizing other services [6]. Investment and Support - The company has attracted investments from notable firms, including Tencent and Gao Rong Capital, which has been involved since 2018 [9][10]. - Gao Rong Capital's managing director highlighted the company's rapid growth and adaptability in a competitive market [12][13].

Core Viewpoint - The article emphasizes the long-term value of Youjia Innovation Technology Co., Ltd. and highlights the commitment of cornerstone investor Kang Chengheng International Investment Co., Ltd. to hold shares without immediate reduction after the lock-up period, reflecting confidence in the company's technology and industry prospects [2][3]. Company Overview - Youjia Innovation is recognized as the "first stock of integrated cockpit and driving," focusing on intelligent assisted driving and smart cockpit fields, with capabilities ranging from L1 to L4 autonomous driving [4]. - The company has established partnerships with 35 major automotive manufacturers, including Chery, Changan, SAIC, and Volkswagen, for mass production of its solutions [4]. Financial Performance - For 2024, Youjia Innovation reported revenue of 654 million yuan, a year-on-year increase of 37.4%. The revenue from intelligent driving solutions was 484 million yuan, up 25.2%, accounting for 73.9% of total revenue. The intelligent cockpit solutions revenue surged to 104 million yuan, reflecting a growth of 467.8% [4]. Market Position and Growth Potential - Youjia Innovation's stock price has increased by over 50% this year, with a market capitalization exceeding 11 billion yuan. Recent reports from CITIC Lyon, Everbright Securities, and Guozheng International have rated the company positively, citing its comprehensive self-research capabilities in autonomous driving solutions [5]. - Guozheng International noted that Youjia Innovation's strong product lineup and customer matrix position it for significant performance elasticity in the future [5]. - CITIC Lyon projected a compound annual growth rate of 49% for total revenue from fiscal years 2024 to 2027, with a target price of 32.00 HKD [5]. Industry Outlook - According to a McKinsey report, the global intelligent driving market is expected to exceed 600 billion USD by 2027, with China's L2-level intelligent driving new car coverage surpassing 57%. The supportive policies for smart connected vehicles further enhance the growth potential of the intelligent driving sector [5].